AC
PTCT icon

Armistice Capital’s PTC Therapeutics PTCT Stock Holding History

Armistice Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.6M Buy
+390,000
New +$27.6M 0.47% 37

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's PTCT Position: Q1 2026 in Review

Armistice Capital reduced its PTC Therapeutics (PTCT) stake by 26% in Q1 2026, selling an estimated $51.5M and leaving 2,074,449 shares worth $141M. The position accounts for 2.51% of the portfolio, ranked #4.

Armistice Capital first reported a position in PTCT in Q4 2018 and has held it in 29 quarters since. The position peaked at $288M in Q4 2024. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Armistice Capital held 2,074,449 shares of PTC Therapeutics worth $141M as of Q1 2026.
  • Armistice Capital sold 727,420 PTC Therapeutics shares in Q1 2026, an estimated $51.5M.
  • PTC Therapeutics made up 2.51% of Armistice Capital's portfolio in Q1 2026, its #4 holding.
  • Armistice Capital first reported a position in PTC Therapeutics in Q4 2018 and has held it in 29 quarters since.
  • Armistice Capital's PTC Therapeutics position peaked at $288M in Q4 2024.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.